Brokerages Set Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Price Target at $973.13

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Get Free Report) have been assigned an average rating of "Moderate Buy" from the twenty-five research firms that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, six have assigned a hold rating, sixteen have given a buy rating and two have given a strong buy rating to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $966.88.

A number of equities research analysts have recently weighed in on REGN shares. Bernstein Bank dropped their target price on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a report on Tuesday, February 4th. BMO Capital Markets cut their price target on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an "overweight" rating for the company in a research note on Tuesday, February 4th. Bank of America restated an "underperform" rating and set a $565.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 10th. TD Cowen dropped their price objective on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a "buy" rating for the company in a report on Tuesday, February 4th. Finally, UBS Group lowered Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and reduced their target price for the stock from $1,130.00 to $738.00 in a report on Thursday, January 16th.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN traded up $8.60 during trading hours on Friday, hitting $625.60. The company had a trading volume of 899,886 shares, compared to its average volume of 679,610. The firm has a market cap of $68.39 billion, a price-to-earnings ratio of 16.34, a PEG ratio of 2.34 and a beta of 0.27. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The business has a fifty day moving average of $680.43 and a 200-day moving average of $786.93. Regeneron Pharmaceuticals has a 12 month low of $603.47 and a 12 month high of $1,211.20.

Remove Ads

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $11.21 by $0.86. The company had revenue of $3.79 billion during the quarter, compared to analysts' expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business's revenue was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $11.86 earnings per share. Equities analysts anticipate that Regeneron Pharmaceuticals will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were paid a dividend of $0.88 per share. The ex-dividend date of this dividend was Thursday, February 20th. This represents a $3.52 annualized dividend and a yield of 0.56%. Regeneron Pharmaceuticals's dividend payout ratio is currently 2.30%.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Large investors have recently bought and sold shares of the stock. RK Asset Management LLC grew its stake in Regeneron Pharmaceuticals by 25.8% in the first quarter. RK Asset Management LLC now owns 12,563 shares of the biopharmaceutical company's stock valued at $7,968,000 after acquiring an additional 2,574 shares during the period. Centre Asset Management LLC acquired a new stake in Regeneron Pharmaceuticals in the 1st quarter valued at $7,740,000. MassMutual Private Wealth & Trust FSB increased its stake in Regeneron Pharmaceuticals by 2.4% during the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 4,166 shares of the biopharmaceutical company's stock valued at $2,642,000 after purchasing an additional 97 shares in the last quarter. DSG Capital Advisors LLC acquired a new position in Regeneron Pharmaceuticals during the fourth quarter worth $603,000. Finally, 111 Capital bought a new position in shares of Regeneron Pharmaceuticals in the fourth quarter valued at $378,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.